PDCD1 and neoplasm: After tumor histological dissection, we further found that delivery of MIT induced substantial expression of PD‐L1 in the tumor foci, a process markedly counteracted when MIT was co‐administered with AREG mAb but not a PD‐L1/PD‐1‐targeting agent such as atezolizumab (Figure 6i).